eggXYt licenses GEiGS® to develop avian flu resistance in chickens


eggXYt licenses the GEiGS™ Technology Platform from Tropic Biosciences in a groundbreaking project to develop resistance against Avian Influenza Virus in chickens

eggXYt, a biotechnology company revolutionizing the livestock industry, and Tropic Biosciences (“Tropic”), the pioneering agricultural-biotechnology company, today announce a license agreement to apply Tropic’s Gene Editing induced Gene Silencing (GEiGS™) technology to develop genetic resistance in chickens against Avian Influenza virus.

Avian Influenza virus is one of the deadliest and most costly avian diseases. The 2015 outbreak in the U.S., for example, led to the slaughter of 50 million poultry and is estimated to have had an economic cost of $3.2 billion. Outbreaks not only disrupt the protein supply chain, but they also threaten human health as the disease can be transferred from birds to humans and has been documented to lead to severe illness and fatality.

eggXYt brings to the collaboration its proven expertise in accelerating gene editing solutions to disrupt the poultry sector. Over the last four years, eggXYt has developed its flagship product, an innovative solution to determine the sex of chicks before incubation, which is set to save the 4 billion male chicks in the egg layer industry that are currently culled each year due to their inability to lay eggs and because it is not economical to raise them for meat. Through the application of GEiGS®, eggXYt will expand its poultry portfolio beyond its initial product and into the field of animal health. eggXYt has recently moved to a state of the art R&D facility and is set to launch a fundraising round, which will support its R&D programs and path to commercialization.

Yehuda Elram, CEO & Co-Founder of eggXYt commented, “Our primary goal is to improve animal welfare and efficiency within the poultry industry, and we are excited to embark on this project that broadens our platform of gene editing solutions for animal health.” He went on to say “Following the COVID-19 outbreak, we are all very mindful of the threat of zoonotic diseases to human health and so we are especially motivated to embark on a project that may help to prevent further pandemics.”

Tropic Biosciences developed GEiGS® to support development of its own tropical crops, for example banana plants that are resistant to Panama disease, a devastating fungal disease that is threatening production globally. Recognizing the wider potential of GEiGS® beyond tropical crops, Tropic has been making the proprietary technology platform commercially available to other innovative companies, including world leaders in the crop and livestock breeding industries.

Eyal Maori, Chief Science Officer and Co-Founder of Tropic Biosciences, commented: “The GEiGS® platform harnesses naturally occurring defense mechanisms to directly attack disease agents, solving the heavy burden of target gene discovery for gene editing applications. This is driving extensive interest in the technology from outside parties and we are delighted to partner with eggXYt and other innovative companies from the broader agricultural and life-sciences industries.”

Tropic and eggXYt’s collaboration comes at an exciting time for gene editing, just after Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for the development of CRISPR.


About eggXYt

eggXYt’s mission is to enable a sustainable future in the livestock industry. eggXYt’s flagship product is a proprietary CRISPR based technology, which allows for non-invasive pre-incubation sex detection in chicken eggs – saving 4 billion male chicks from being unnecessarily hatched and disposed of each year, saving the industry billions of dollars and adding 4 billion eggs to the global supply. eggXYt was recently selected as a Sustainable Food Systems Challenge Solver team by MIT Solve. eggXYt was founded in 2016 and is based in Jerusalem & Tel Aviv, Israel.

For more information, please visit  or contact.


About Tropic Biosciences

Tropic Biosciences is one of the leading agricultural gene-editing companies globally, and focuses on the development and commercialization of high-performing varieties of tropical crops, namely coffee, bananas and rice. It employs over 80 industry-leading professionals and is headquartered at the renowned Norwich Research Park.

For more information please visit or contact


About GEiGS®

GEiGS® (Genome Editing induced Gene Silencing) technology utilizes established genome editing tools (e.g. CRISPR, TALEN) to make precise and specific changes to only a few nucleotides within non-coding genomic locations of a host organism. These changes redirect RNA interference (RNAi, also Gene Silencing) activity of non-coding genes towards desired target genes, actively suppressing their activity.

Target genes can include the host’s own genes, or gene-families, to finely tune their expression to a new desired level. Further, GEiGS® can be used to activate defense against pathogens and pests (e.g.viruses and fungi) by redirecting RNAi activity towards pathogen and pest genes. GEiGS® does not depend on the introduction of foreign genes into the host genome, and thus the approach will be considered as non-GMO in multiple regions.

Key benefits of GEiGS®

  • Key Benefits Icon
    Precise, predictable, and stable tuning of target gene expression

    By redirecting the silencing activity of the host’s own non-coding genes, GEiGS® introduces novel RNAi activity with highly programmable potency and tissue specificity. This elegant approach requires only minimal changes to the host’s genome (less than 20 nucleotides), thus avoiding transcriptional gene silencing and allowing for highly stable RNAi activity over time and across generations.

  • Key Benefits Icon
    Accelerated development of critical disease and pest resistance traits

    GEiGS® can be used to redirect the silencing activity of the host’s native non-coding genes towards well characterized and highly conserved viral, fungal or pest genes. This distinctly direct approach significantly accelerates product development time while minimizing pleiotropic effects associated with editing the host’s coding genes.

  • Key Benefits Icon
    Favourable regulatory classification in multiple markets

    GEiGS® technology does not involve the insertion of DNA sequences from other organisms (‘Foreign DNA’) into the host genome and does not impact the sequence of proteins. These factors allow for a non-GM classification in multiple major markets and a more streamlined regulatory approval process.

  • Key Benefits Icon
    Universal platform that works with existing gene editing tools

    GEiGS® is not dependent on any one specific gene editing tool, but instead can be deployed by using a broad range of different nucleases. This provides the user with freedom to choose which gene editing tools they use to implement GEiGS® edits – tools that may already be applied in their existing pipelines.

Find out how GEiGS® technology can benefit you

How our users benefit from using the GEiGS® platform

Our global collaborators include

Interested in partnering with us?

Access the GEiGS® platform

We collaborate with world-leading companies and academic institutions, enabling them to access our pioneering GEiGS® technology to address some of the most pressing agricultural production challenges.

Contact us today to discuss GEiGS® licensing and service options and join us in driving innovation forward. +44 (0)1603 274441